+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Phenylketonuria Treatment Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5148016
Global Phenylketonuria Treatment Market Size, Share & Trends Analysis Report by Drug Type (Kuvan, Playnziq, and Others), Forecast Period 2020-2026.

In 2019, the Global phenylketonuria (PKU) treatment market was around570 million and is anticipated to grow at a lucrative growth rate during the forecast period. Phenylketonuria is a type of rare genetic disorder which have no specific cure till now. However, with the controlled diet and use of medication, PKU is can be managed successfully. In addition to this, various additional therapies are also being used for the management of PKU, which is expected to significantly drive the phenylketonuria treatment market during the forecast period.

The global phenylketonuria treatment market is segmented on the basis of drug type into kuvan, playnziq, and others. Kuvan holds most of the market share in 2019. However, playnziq is expected to witness a considerable market growth rate during the forecast period. The global phenylketonuria treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to hold a major market share during the forecast period. The well-established healthcare sector and significant approvals by the US FDA for the various new novel drugs and therapies used in the treatment of PKU is anticipated to provide a significant market share to the region. Moreover, Asia-Pacific is expected to witness considerable market growth during the forecast period.

Phenylketonuria treatment market is a consolidated market, however significant opportunities for the new entrants are present in the market. The key players acting in the market include BioMarin Pharmaceutical Inc., Censa Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd., Pluvia AS, Synlogic Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger & acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the global phenylketonuria treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for the government organizations, pharmaceutical companies, healthcare industry, PKU food manufacturing companies, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
  • Global Phenylketonuria treatment Market Research and Analysis by Drug Type

The Report Covers:
  • Comprehensive research methodology of the global phenylketonuria treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global phenylketonuria treatment market.
  • Insights about market determinants which are stimulating the global phenylketonuria treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Phenylketonuria Treatment Market by Drug Type
5.1.1. Kuvan
5.1.2. Playnziq Others
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. American Gene Technologies Inc.
7.2. APR Applied Pharma Research s.a.
7.3. BioMarin Pharmaceutical Inc.
7.4. Censa Pharmaceuticals Inc.
7.5. Codexis, Inc.
7.6. Daiichi Sankyo Co.Ltd.
7.7. Erytech Pharma SA
7.8. Generation Bio Co.
7.9. Homology Medicines, Inc.
7.10. Nestlé Health Science
7.11. Nutricia Ltd. (Danone S.A.)
7.12. Par Pharmaceutical Inc.
7.13. Pluvia AS
7.14. REGENXBIO Inc.
7.15. Retrophin, Inc.
7.16. SOMInnovation Biotech, SA
7.17. Synlogic, Inc.
7.18. Synthetic Biologics, Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • American Gene Technologies Inc.
  • APR Applied Pharma Research s.a.
  • BioMarin Pharmaceutical Inc.
  • Censa Pharmaceuticals Inc.
  • Codexis, Inc.
  • Daiichi Sankyo Co.Ltd.
  • Erytech Pharma SA
  • Generation Bio Co.
  • Homology Medicines, Inc.
  • Nestlé Health Science
  • Nutricia Ltd. (Danone S.A.)
  • Par Pharmaceutical Inc.
  • Pluvia AS
  • Retrophin, Inc.
  • SOMInnovation Biotech, SA
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.